Also, NGS performed on APL patients with alternative RARA or RARG fusions revealed more mutations of KMT2C, K-RAS, and GATA2, but fewer mutations of FLT3-ITD when compared to APL patients with PML-RARA fusion [167]. This evidence concerns the gene RARA and acute promyelocytic leukemia.